Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid

References

• Al-Toubah T, Morse B, Strosberg J. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms. Oncologist. 2020;25(1):e48–e52. doi:10.1634/theoncologist.2019-0361.
   PubMed Web of Science ®Google Scholar
• Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, et al. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(). Ann Oncol. 2021;32(4):439–451. doi:10.1016/j.annonc.2021.01.003.
   PubMed Web of Science ®Google Scholar
• Espinosa-Olarte P, La Salvia A, Riesco-Martinez MC, Anton-Pascual B, Garcia-Carbonero R. Chemotherapy in Nen: still has a role? Rev Endocr Metab Disord. 2021;22(3):595–614. doi:10.1007/s11154-021-09638-0.
   PubMed Web of Science ®Google Scholar
• La Salvia A, Espinosa-Olarte P, Riesco-Martinez MDC, Anton-Pascual B, Garcia-Carbonero R. Targeted Cancer Therapy: what’s New in the Field of Neuroendocrine Neoplasms? Cancers (Basel). 2021;13(7):1701. doi:10.3390/cancers13071701.
   PubMed Web of Science ®Google Scholar
• Gosain R, Mukherjee S, Yendamuri SS, Iyer R. Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. Cancers (Basel). 2018;10(12):510. doi:10.3390/cancers10120510.
   PubMed Web of Science ®Google Scholar
• Naraev BG, Ramirez RA, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids. Clin Lung Cancer. 2019;20(3):e376–e92. doi:10.1016/j.cllc.2019.02.007.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, et al. Pulmonary neuroendocrine (carcinoid) tumors: european Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–1620. doi:10.1093/annonc/mdv041.
   PubMed Web of Science ®Google Scholar
• Burkhart RA, Baker LA, Tiriac H. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: pharmacotyping. Methods Mol Biol. 2018;1787:253–261.
   PubMedGoogle Scholar
• Lee JK, Liu Z, Sa JK, Shin S, Wang J, Bordyuh M, Cho HJ, Elliott O, Chu T, Choi SW, et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat Genet. 2018;50(10):1399–1411. doi:10.1038/s41588-018-0209-6.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Stewart DJ. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 2017;23(5):1137–1148. doi:10.1158/1078-0432.CCR-16-1968.
   PubMed Web of Science ®Google Scholar
• Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer. 2014;50(4):706–712. doi:10.1016/j.ejca.2013.11.032.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212–3218. doi:10.1200/JCO.2012.47.2464.
   PubMed Web of Science ®Google Scholar
• Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, et al. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)–a phase II non-randomised trial. Eur J Cancer. 2014;50(18):3107–3115. doi:10.1016/j.ejca.2014.10.001.
   PubMed Web of Science ®Google Scholar
• Li T, Kang G, Wang T, Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 2018;16(1):687–702. doi:10.3892/ol.2018.8733.
   PubMed Web of Science ®Google Scholar
• Lopes-Coelho F, Martins F, Pereira SA, Serpa J. Anti-Angiogenic Therapy: current Challenges and Future Perspectives. Int J Mol Sci .2021;22(7):3765. doi:10.3390/ijms22073765.
   PubMed Web of Science ®Google Scholar
• Kuczynski EA, Vermeulen PB, Pezzella F, Kerbel RS, Reynolds AR. Vessel co-option in cancer. Nat Rev Clin Oncol. 2019;16(8):469–493. doi:10.1038/s41571-019-0181-9.
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26(8):1316–1323. doi:10.1200/JCO.2007.13.6374.
   PubMed Web of Science ®Google Scholar
• Scoazec JY. Angiogenesis in neuroendocrine tumors: therapeutic applications. Neuroendocrinology. 2013;97(1):45–56. doi:10.1159/000338371.
   PubMed Web of Science ®Google Scholar
• Xu J, Shen L, Bai C, Wang W, Li J, Yu X, Li Z, Li E, Yuan X, Chi Y, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1489–1499. doi:10.1016/S1470-2045(20)30493-9.
   PubMed Web of Science ®Google Scholar
• Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1500–1512. doi:10.1016/S1470-2045(20)30496-4.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513. doi:10.1056/NEJMoa1003825.
   PubMed Web of Science ®Google Scholar
• Blumenthal GM, Cortazar P, Zhang JJ, Tang S, Sridhara R, Murgo A, Justice R, Pazdur R. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist. 2012;17(8):1108–1113. doi:10.1634/theoncologist.2012-0044.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Benavent M, Fonseca PJ, Castellano D, Alonso T, Teule A, Custodio A, Tafuto S, La Casta Munoa A, Spada F, et al. A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107). Journal of Clinical Oncology. 2021;39(3_suppl):360. doi:10.1200/JCO.2021.39.3_suppl.360.
   Web of Science ®Google Scholar
• Bergsland EK, Mahoney MR, Asmis TR, Hall N, Kumthekar P, Maitland ML, Niedzwiecki D, Nixon AB, O’Reilly EM, Schwartz LH, et al. Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Journal of Clinical Oncology. 2019;37(15_suppl):4005. doi:10.1200/JCO.2019.37.15_suppl.4005.
   Web of Science ®Google Scholar
• Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D’Avolio A, et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer. 2014;14(1):184. doi:10.1186/1471-2407-14-184.
   PubMedGoogle Scholar
• Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J Pathol. 2017;241(3):362–374. doi:10.1002/path.4845.
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603. doi:10.1038/nrc2442.
   PubMed Web of Science ®Google Scholar
• Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8(4):210–221. doi:10.1038/nrclinonc.2011.21.
   PubMed Web of Science ®Google Scholar
• Nassar D, Blanpain C. Cancer Stem Cells: basic Concepts and Therapeutic Implications. Annu Rev Pathol. 2016;11(1):47–76. doi:10.1146/annurev-pathol-012615-044438.
   PubMedGoogle Scholar
• Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, Lee YK, Kwon HY. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells Int. 2018:5416923. doi:10.1155/2018/5416923
   PubMed Web of Science ®Google Scholar
• Yang M, Fang X, Li J, Xu D, Xiao Q, Yu S, Hu H, Weng S, Ding K, Yuan Y. Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. Cancer Biol Ther. 2019;20(4):391–396. doi:10.1080/15384047.2018.1529120.
   PubMed Web of Science ®Google Scholar
• Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 2014;344(1):1–12. doi:10.1016/j.canlet.2013.10.010.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Paz K, Schwartz GK, Wexler LH, Maki R, Pollock RE, Morris R, Cohen R, Shankar A, Blackman G, et al. Patient-derived xenografts for individualized care in advanced sarcoma. Cancer. 2014;120(13):2006–2015. doi:10.1002/cncr.28696.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011;10(8):1311–1316. doi:10.1158/1535-7163.MCT-11-0233.
   PubMed Web of Science ®Google Scholar
• Kiyohara Y, Yoshino K, Kubota S, Okuyama H, Endo H, Ueda Y, Kimura T, Kimura T, Kamiura S, Inoue M, et al. Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer. Cancer Sci. 2016;107(4):452–460. doi:10.1111/cas.12898.
   PubMed Web of Science ®Google Scholar
• van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, Van houdt W, Van gorp J, Taylor-Weiner A, Kester L, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933–945. doi:10.1016/j.cell.2015.03.053.
   PubMed Web of Science ®Google Scholar